
This week in drug discovery (23-27 January)
News round-up for 23-27 January by DDW Digital Content Editor Diana Spencer. Cell and gene therapies have been making the news this week, as we launch our very own guide to global… Read More

News round-up for 23-27 January by DDW Digital Content Editor Diana Spencer. Cell and gene therapies have been making the news this week, as we launch our very own guide to global… Read More

CARsgen Therapeutics and Huadong Medicine (Hangzhou) will collaborate on the commercialisation of CARsgen's BCMA CAR-T product CT053 in mainland China. CT053 (zevorcabtagene autoleucel, Zevor-cel) is CARsgen's lead drug candidate and an autologous CAR T cell product treating relapsed/refractory multiple myeloma (R/R MM). Dr Zonghai Li, Chairman of the Board, Chief… Read More

CAR-T cell therapies are a promising approach for treating solid tumours. But identifying appropriate T-cell receptor (TCR) domains that exclusively target tumour antigens remains a challenge. Toxicity, tumour activation, and tumour persistence are significant challenges to using CAR-T cell therapies for solid tumours. In this new on-demand… Read More

CAR-T cell therapies are a promising approach for treating solid tumours. But identifying appropriate T-cell receptor (TCR) domains that exclusively target tumour antigens remains a challenge. Toxicity, tumour activation, and tumour persistence are significant challenges to using CAR-T cell therapies for solid tumours. In this webinar, Twist Bioscience’s CSO, Aaron… Read More

DDW highlights the most interesting global news and comments within the drug discovery and development sector this month. Everyone enjoys a good news story and the drug discovery and development sector is no exception. Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening… Read More

CAR-T therapy can be used to eliminate unwanted cells that cause autoimmunity, according to the results of a new study in mice with an autoimmune disease similar to multiple sclerosis (MS). CAR-T, which uses genetically altered immune cells to destroy cancer cells, has revolutionised treatment of some… Read More

This 28-page eBook sponsored by Twist Bioscience features insights and expert opinions on the latest advancements occurring in immuno-oncology and drug discovery. Read this eBook to learn about: The challenges and opportunities facing CAR-T cell therapies Targeting GPCRs in cancer drug discovery The immuno-oncology landscape and its many pathways Access… Read More

This latest 28 page eBook sponsored by Twist Bioscience features insights and expert opinions on the latest advancements occurring in immuno-oncology and drug discovery. Read this eBook to learn about: The challenges and opportunities facing CAR-T cell therapies Targeting GPCRs in cancer drug discovery The immuno-oncology landscape and its many… Read More

Listen to this article on the DDW podcast: Alongside industry professionals interested in the cell and gene therapy landscape in Europe, DDW’s Multimedia Editor Megan Thomas was welcomed to Advanced Therapies Europe 2022 by Phacilitate’s Vice President, Becky Johnson-Kent. Johnson-Kent introduced the notion of the zebra company and compared its two-fold… Read More

The European Commission (EC) has approved biotechnology company Kite’s CAR T-cell therapy Yescarta for patients with follicular lymphoma (FL). Specifically the approval is for adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy. The approval was based… Read More

News round-up by DDW’s Reece Armstrong for 6-10 June Antibiotic developments, vaccines for MMR and business expansions are some of the features of this week’s news round-up. US gets another MMR vaccine option in GSK’s Priorix GSK’s vaccine for the prevention of measles, mumps and rubella (MMR) has been… Read More

Biopharmaceutical company Kite has announced long-term follow up results of two studies for its CAR T-cell therapy Tecartus (brexucabtagene autoleucel). The results of both a three- and two-year follow-up of the company’s ZUMA trial were announced at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. … Read More

This guide examines how cell and gene therapy transform cancer treatment. While cell therapies like CAR-T are promising cancer treatments, many challenges remain, including improving responses in blood cancers and efficacy in solid tumours. This new cancer therapy guide from 10x Genomics will outline: Cutting-edge single cell and spatial analysis technologies… Read More

A study from researchers in the Perelman School of Medicine at the University of Pennsylvania has shown that an experimental immunotherapy can temporarily reprogramme patients’ immune cells to attack a specific target via only a single injection of mRNA, similar to the mRNA-based Covid-19 vaccines. Context The researchers, whose… Read More

Janssen Pharmaceutical has recently filed for B-cell maturation antigen (BCMA) CAR-T therapy Cilta-cel in Japan. Earlier in March 2021, Bristol-Myers Squibb (BMS) filed for the first BCMA CAR-T therapy idecabtagene vicleucel, in the country. Following approval by the Japanese regulatory authority, BMS will have the first-mover advantage. However, stiff competition is expected… Read More

Chimeric Antigen Receptor or CAR-T cells, a new form of immunotherapy with genetically engineered immune system cells, has been approved for the treatment of multiple myeloma, a type of blood cancer. Context In a case study published in Nature Medicine, Sinai scientists reported a… Read More